Competing interests
Matinas
HEART
G.F.W. (corresponding author) reports personal fees for lectures from Amgen, Novartis and Sanofi; research grants from Amgen and Arrowhead Pharmaceuticals; and honoraria for serving on advisory boards from Amgen, AstraZeneca, Esperion, Novartis, Pfizer and Arrowhead Pharmaceuticals. J.H., B.G., S.M., J.S.M., T.C. and R.Z. are, or were recently, Arrowhead Pharmaceuticals employees and shareholders. I.G. reports being on advisory boards for Arrowhead Pharmaceuticals and Ionis. C.B. reports grant/research support (all substantial (>$10,000) and all paid to institution, not individual) from Akcea, Amgen, Arrowhead Pharmaceuticals, Esperion, Ionis, Merck, Novartis, Novo Nordisk, Regeneron and National Institutes of Health and consultant for 89Bio, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Denka Seiken*, Eli Lilly, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma, Merck, New Amsterdam*, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi-Synthelabo (*substantial where noted). P.G. reports being principal investigator for Verve101 and receiving consulting fees from Verve Therapeutics. R.H. reports consulting fees from Acasti, Akcea/Ionis, Amgen, Amryt, Arrowhead Pharmaceuticals, Boston Heart, HLS Therapeutics, Pfizer, Novartis, Regeneron, Sanofi and Ultragenyx. D.G. reports grants and/or personal fees from Arrowhead Pharmaceuticals, Acasti, Amgen, Kowa, Regeneron, Uniqure, Akcea, Allergan, Amryt, CRISPR Therapeutics, Eli Lilly, Ionis, Novartis, Biogen, Sanofi, Novo Nordisk, Pfizer, Verve Therapeutics, Aegerion, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Ceapro, Dalcor, Esperion and The Medicine Company. D.S. reports honoraria for serving on advisory boards from Regeneron, Amgen, AstraZeneca, Amarin, Esperion, Novartis and Sanofi, outside the submitted work. No competing interests are reported by C.S., P.C., R.S., J.B. and J.K.